Effect of blue-blocking glasses in major depressive disorder with sleep onset insomnia: A randomized, double-blind, placebo-controlled study

Yuichi Esaki, Tsuyoshi Kitajima, Ippei Takeuchi, Soji Tsuboi, Osamu Furukawa, Masatsugu Moriwaki, Kiyoshi Fujita, Nakao Iwata

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Blue wavelengths form the portion of the visible electromagnetic spectrum that most potently regulates circadian rhythm. We hypothesized that wearing blue-blocking (BB) glasses in the evening may influence circadian rhythm disturbances in patients with major depressive disorder (MDD), resulting in improved sleep and mood. We used a randomized placebo-controlled double-blinded design. Patients with MDD with sleep onset insomnia were randomly assigned to wearing either BB glasses or clear glasses (placebo). Patients were instructed to wear the glasses from 20:00 hours until bedtime for 2 weeks. We assessed sleep state (sleep quality on a visual analog scale, the Morningness–Eveningness Questionnaire [MEQ], and a sleep diary) and depressive symptoms at baseline and after 2 weeks. Data were analyzed with a full analysis set. In total, 20 patients were randomly assigned to the BB and placebo groups (BB group, n = 10; placebo group, n = 10). There were three dropouts (BB group, n = 1; placebo group, n = 2). At baseline, sleep quality, sleep latency (assessed via a sleep diary), and antipsychotics use differed between the groups. To take account of these differences, the baseline sleep state or depressive symptoms and antipsychotics use were used as covariates in the later analysis. The change scores for sleep quality did not show a significant improvement in the BB group compared with the placebo group (mean [standard deviation, SD] scores for BB versus placebo: 36.1 [31.7] versus 16.2 [15.1], p = 0.43), although half of the BB group showed a clear improvement in sleep quality. The change in MEQ scores did not significantly differ between the groups (p = 0.14), although there was a trend of a shift to morning type in the BB group (3.10 [4.95] points) and to evening type in the placebo group (0.50 [3.89] points). There were no statistically significant changes in depressive symptoms in either group. Across both groups, 40% of the participants reported pain or discomfort from wearing the glasses, which were available in only one size. Thus, the failure to find significant differences may have resulted from the glasses used in this study. Glasses fitted to individual patients may improve efficacy and safety. Replication of the study with a larger sample size and size-adjustable glasses is needed.

Original languageEnglish
Pages (from-to)753-761
Number of pages9
JournalChronobiology International
Volume34
Issue number6
DOIs
Publication statusPublished - 03-07-2017

Fingerprint

Major Depressive Disorder
Sleep Initiation and Maintenance Disorders
Glass
Sleep
Placebos
Depression
Circadian Rhythm
Antipsychotic Agents
Electromagnetic Phenomena
Visual Analog Scale
Sample Size
Safety
Pain

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)

Cite this

Esaki, Yuichi ; Kitajima, Tsuyoshi ; Takeuchi, Ippei ; Tsuboi, Soji ; Furukawa, Osamu ; Moriwaki, Masatsugu ; Fujita, Kiyoshi ; Iwata, Nakao. / Effect of blue-blocking glasses in major depressive disorder with sleep onset insomnia : A randomized, double-blind, placebo-controlled study. In: Chronobiology International. 2017 ; Vol. 34, No. 6. pp. 753-761.
@article{7a21169ce2534fcf948150d805be54ef,
title = "Effect of blue-blocking glasses in major depressive disorder with sleep onset insomnia: A randomized, double-blind, placebo-controlled study",
abstract = "Blue wavelengths form the portion of the visible electromagnetic spectrum that most potently regulates circadian rhythm. We hypothesized that wearing blue-blocking (BB) glasses in the evening may influence circadian rhythm disturbances in patients with major depressive disorder (MDD), resulting in improved sleep and mood. We used a randomized placebo-controlled double-blinded design. Patients with MDD with sleep onset insomnia were randomly assigned to wearing either BB glasses or clear glasses (placebo). Patients were instructed to wear the glasses from 20:00 hours until bedtime for 2 weeks. We assessed sleep state (sleep quality on a visual analog scale, the Morningness–Eveningness Questionnaire [MEQ], and a sleep diary) and depressive symptoms at baseline and after 2 weeks. Data were analyzed with a full analysis set. In total, 20 patients were randomly assigned to the BB and placebo groups (BB group, n = 10; placebo group, n = 10). There were three dropouts (BB group, n = 1; placebo group, n = 2). At baseline, sleep quality, sleep latency (assessed via a sleep diary), and antipsychotics use differed between the groups. To take account of these differences, the baseline sleep state or depressive symptoms and antipsychotics use were used as covariates in the later analysis. The change scores for sleep quality did not show a significant improvement in the BB group compared with the placebo group (mean [standard deviation, SD] scores for BB versus placebo: 36.1 [31.7] versus 16.2 [15.1], p = 0.43), although half of the BB group showed a clear improvement in sleep quality. The change in MEQ scores did not significantly differ between the groups (p = 0.14), although there was a trend of a shift to morning type in the BB group (3.10 [4.95] points) and to evening type in the placebo group (0.50 [3.89] points). There were no statistically significant changes in depressive symptoms in either group. Across both groups, 40{\%} of the participants reported pain or discomfort from wearing the glasses, which were available in only one size. Thus, the failure to find significant differences may have resulted from the glasses used in this study. Glasses fitted to individual patients may improve efficacy and safety. Replication of the study with a larger sample size and size-adjustable glasses is needed.",
author = "Yuichi Esaki and Tsuyoshi Kitajima and Ippei Takeuchi and Soji Tsuboi and Osamu Furukawa and Masatsugu Moriwaki and Kiyoshi Fujita and Nakao Iwata",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/07420528.2017.1318893",
language = "English",
volume = "34",
pages = "753--761",
journal = "Chronobiology International",
issn = "0742-0528",
publisher = "Informa Healthcare",
number = "6",

}

Effect of blue-blocking glasses in major depressive disorder with sleep onset insomnia : A randomized, double-blind, placebo-controlled study. / Esaki, Yuichi; Kitajima, Tsuyoshi; Takeuchi, Ippei; Tsuboi, Soji; Furukawa, Osamu; Moriwaki, Masatsugu; Fujita, Kiyoshi; Iwata, Nakao.

In: Chronobiology International, Vol. 34, No. 6, 03.07.2017, p. 753-761.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of blue-blocking glasses in major depressive disorder with sleep onset insomnia

T2 - A randomized, double-blind, placebo-controlled study

AU - Esaki, Yuichi

AU - Kitajima, Tsuyoshi

AU - Takeuchi, Ippei

AU - Tsuboi, Soji

AU - Furukawa, Osamu

AU - Moriwaki, Masatsugu

AU - Fujita, Kiyoshi

AU - Iwata, Nakao

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Blue wavelengths form the portion of the visible electromagnetic spectrum that most potently regulates circadian rhythm. We hypothesized that wearing blue-blocking (BB) glasses in the evening may influence circadian rhythm disturbances in patients with major depressive disorder (MDD), resulting in improved sleep and mood. We used a randomized placebo-controlled double-blinded design. Patients with MDD with sleep onset insomnia were randomly assigned to wearing either BB glasses or clear glasses (placebo). Patients were instructed to wear the glasses from 20:00 hours until bedtime for 2 weeks. We assessed sleep state (sleep quality on a visual analog scale, the Morningness–Eveningness Questionnaire [MEQ], and a sleep diary) and depressive symptoms at baseline and after 2 weeks. Data were analyzed with a full analysis set. In total, 20 patients were randomly assigned to the BB and placebo groups (BB group, n = 10; placebo group, n = 10). There were three dropouts (BB group, n = 1; placebo group, n = 2). At baseline, sleep quality, sleep latency (assessed via a sleep diary), and antipsychotics use differed between the groups. To take account of these differences, the baseline sleep state or depressive symptoms and antipsychotics use were used as covariates in the later analysis. The change scores for sleep quality did not show a significant improvement in the BB group compared with the placebo group (mean [standard deviation, SD] scores for BB versus placebo: 36.1 [31.7] versus 16.2 [15.1], p = 0.43), although half of the BB group showed a clear improvement in sleep quality. The change in MEQ scores did not significantly differ between the groups (p = 0.14), although there was a trend of a shift to morning type in the BB group (3.10 [4.95] points) and to evening type in the placebo group (0.50 [3.89] points). There were no statistically significant changes in depressive symptoms in either group. Across both groups, 40% of the participants reported pain or discomfort from wearing the glasses, which were available in only one size. Thus, the failure to find significant differences may have resulted from the glasses used in this study. Glasses fitted to individual patients may improve efficacy and safety. Replication of the study with a larger sample size and size-adjustable glasses is needed.

AB - Blue wavelengths form the portion of the visible electromagnetic spectrum that most potently regulates circadian rhythm. We hypothesized that wearing blue-blocking (BB) glasses in the evening may influence circadian rhythm disturbances in patients with major depressive disorder (MDD), resulting in improved sleep and mood. We used a randomized placebo-controlled double-blinded design. Patients with MDD with sleep onset insomnia were randomly assigned to wearing either BB glasses or clear glasses (placebo). Patients were instructed to wear the glasses from 20:00 hours until bedtime for 2 weeks. We assessed sleep state (sleep quality on a visual analog scale, the Morningness–Eveningness Questionnaire [MEQ], and a sleep diary) and depressive symptoms at baseline and after 2 weeks. Data were analyzed with a full analysis set. In total, 20 patients were randomly assigned to the BB and placebo groups (BB group, n = 10; placebo group, n = 10). There were three dropouts (BB group, n = 1; placebo group, n = 2). At baseline, sleep quality, sleep latency (assessed via a sleep diary), and antipsychotics use differed between the groups. To take account of these differences, the baseline sleep state or depressive symptoms and antipsychotics use were used as covariates in the later analysis. The change scores for sleep quality did not show a significant improvement in the BB group compared with the placebo group (mean [standard deviation, SD] scores for BB versus placebo: 36.1 [31.7] versus 16.2 [15.1], p = 0.43), although half of the BB group showed a clear improvement in sleep quality. The change in MEQ scores did not significantly differ between the groups (p = 0.14), although there was a trend of a shift to morning type in the BB group (3.10 [4.95] points) and to evening type in the placebo group (0.50 [3.89] points). There were no statistically significant changes in depressive symptoms in either group. Across both groups, 40% of the participants reported pain or discomfort from wearing the glasses, which were available in only one size. Thus, the failure to find significant differences may have resulted from the glasses used in this study. Glasses fitted to individual patients may improve efficacy and safety. Replication of the study with a larger sample size and size-adjustable glasses is needed.

UR - http://www.scopus.com/inward/record.url?scp=85019131796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019131796&partnerID=8YFLogxK

U2 - 10.1080/07420528.2017.1318893

DO - 10.1080/07420528.2017.1318893

M3 - Article

C2 - 28488943

AN - SCOPUS:85019131796

VL - 34

SP - 753

EP - 761

JO - Chronobiology International

JF - Chronobiology International

SN - 0742-0528

IS - 6

ER -